RxDoctor Payments Data

Don Henslee, MD

Urology · Fairbury, NENPI 1285657551

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.9%), other and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Angiodynamics, Inc. at 38.4% of the total. 2025 is the largest year on record at $6,397, 3.0 times the $2,128 reported in 2019.

$14,741in general payments, 2019–2025

Across 267 payments — averaging $55.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$6K
  • Teleflex LLC$3K
  • Neotract Inc.$2K
  • Sumitomo Pharma America, Inc.$565
  • Isoray, Inc$376
  • Johnson & Johnson$353
  • plus $3K from 42 others

What the payments were for

  • Speaking & faculty fees$1061%
  • Travel & lodging$2,64218%
  • Food & beverage$6,17542%
  • Education$1791%
  • Other$5,63938%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,741 in reported general payments places this provider in the 85th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$161,270
Medicare patients
576
Services billed
3,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide36$476,470
MyrbetriqMirabegron107$51,313
GemtesaVibegron30$20,915
XareltoRivaroxaban13$7,399
EliquisApixaban14$4,152
Finasteride385$3,662
Tolterodine Tartrate ErTolterodine Tartrate37$2,338
Tamsulosin Hcl183$2,110
Fesoterodine Fumarate ErFesoterodine Fumarate13$2,102
Potassium Citrate ErPotassium Citrate17$1,981
Methenamine Hippurate30$1,537
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst54$1,046
Solifenacin Succinate21$943
Alfuzosin Hcl ErAlfuzosin Hcl44$843
Oxybutynin Chloride ErOxybutynin Chloride30$833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$345$527,783143 claims
Sumitomo Pharma America, Inc.Gemtesa$565$20,91530 claims
Johnson & JohnsonXarelto$353$7,39913 claims
PfizerEliquis$340$4,15214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 urology providers in Nebraska.

Other urology in Fairbury

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →